Neither clinicians nor patients like the idea of “one-size-fits-all” health care. Recently, the concept of “personalized medicine,” also called “precision medicine,” has been popularized. Personalized medicine involves tailoring the diagnosis and treatment to the risks of disease and likelihood of response to treatments for individuals, rather than populations.
Read more about what “personalized medicine” really means
About 1 in 3 adults ages 50 to 75 have never been screened for colon cancer or isn’t up-to-date with recommended screenings. Screening lowers the risk of death from colon cancer, and experts encourage people with no family history to start regular screening at age 50.
Read more about choosing the right screening test for colon cancer
Shared decision making (SDM) continues to gain great momentum through the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and Meaningful Use (MU), but a proposed change to the MU requirement for Stage 3 threatens that progress.
Read more about why shared decision making isn’t “topped out.”
In April 2015, President Obama signed into law the Medicare Access and CHIP Reauthorization Act of 2015, simply called MACRA. Unlike the Affordable Care Act (“ObamaCare”), the MACRA bill had rare, overwhelming bipartisan support, with a final vote of 392-37 in the House and 92-8 in the Senate.
Read more about how patients and families can benefit under MACRA
Steve Atlas, one of our medical editors and a primary care provider at Massachusetts General Hospital, recently wrote a perspective piece in Spine that got me thinking about shared decision making as a way to strengthen the relationships between providers and patients.
Read more about shared decision making for spinal fusion
Two weeks ago, The New York Times published a story about a change in the way prostate cancer is treated. Today, almost half of men diagnosed with early-stage prostate cancer are able to avoid surgery and radiation by making an informed choice to opt for active surveillance instead.
Read more about the shift in prostate cancer treatment
I recently returned from the American College of Physicians (ACP) annual meeting in Washington, DC. The ACP is the largest medical specialty organization in the world, with 147,000 members spanning the spectrum from medical students starting off on their careers to seasoned clinicians in practice and medical school professors.
Read more about the ACP’s commitment to patient-centered care
For more than 25 years, the Foundation has been a thought leader in research around outcomes that matter to patients, in advocacy for health system change, and in shared decision making (SDM). Today, we are pleased to introduce the new and improved Foundation website.
Read more about exciting features of the new Foundation website
A review of the 86 trials included in the 2011 Cochrane Review of decision aids found great variability in the reporting of decision aid effectiveness. In some studies, the measures used to evaluate decision quality and other outcomes were not named. In other studies, the decision aid tool itself was not well described, making it hard to know what components were part of the DA.
Read more about the IPDAS Reporting Guidelines Workgroup
Prostate cancer screening has been in the news again lately, and it continues to merit the label of “the controversy that refuses to die.” Let’s review some of the reasons for the recent resurgence in attention around the prostate specific antigen (PSA) test.
Read more about why the prostate cancer screening debate continues